Compare T Rowe Price Group Inc (TROW) vs Health Care Select Sector SPDR Fund (XLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
T Rowe Price Group Inc vs Health Care Select Sector SPDR Fund — how do they compare? T Rowe Price Group Inc trades at $107.71 (market cap $23.34B), while Health Care Select Sector SPDR Fund trades at $167.29. The key difference: T Rowe Price Group Inc pays a 4.75% dividend while Health Care Select Sector SPDR Fund pays none, and Health Care Select Sector SPDR Fund is trading nearer its 52-week high, T Rowe Price Group Inc nearer its low. Which is the better fit depends on your goals.
| TROW | XLV | |
|---|---|---|
Market Cap | $23.34B | — |
Sector | Financials | — |
52-Week High | $121.68 | $175.68 |
52-Week Low | $86.19 | $134.13 |
Enterprise Value | $20.54B | — |
Dividend Yield | 4.75% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
T. Rowe Price (TROW) trades at $109.42, down 0.33% on the day, with a bearish technical signal from moving averages. The stock shows strong fundamentals with a P/E of 10.99, net income margin of 29.26%, and consistent dividend payments. Recent developments include the acquisition of F/m Investments to expand fixed-income ETF capabilities and significant AI adoption across operations. Revenue has grown from $6.5B in 2022 to $7.3B in 2025, with net income reaching $2.09B.
TROW presents a mixed outlook with attractive valuation metrics and solid profitability offset by bearish technical indicators and equity outflows. The consensus price target of $112.50 suggests modest upside potential. Key risks include market-sensitive revenue streams and competitive pressures in asset management. Institutional buying from firms like BlackRock provides support, but investors should weigh the strong fundamentals against near-term technical weakness.
XLV trades at $167.16, down 2.5% amid testing key support levels, with technical indicators showing mixed signals between bullish moving averages and bearish oscillators. The healthcare ETF maintains defensive appeal with upcoming dividend payments and steady institutional interest, though recent options activity shows increased put volume. Healthcare sector momentum remains supported by strong earnings and defensive positioning in volatile markets.
Outlook remains cautiously optimistic given healthcare's defensive characteristics and potential Fed rate hike benefits, though near-term technical weakness and sector-specific headwinds like drug trial failures present risks. The ETF's low expense ratio and diversification across 60 healthcare stocks provide stability for long-term investors seeking sector exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About T Rowe Price Group Inc
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →About Health Care Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.
Read more on XLV →
